Ruling Boxes Alere’s Arriva Unit Into Corner

Attorneys for Arriva Medical agreed in court this morning they have few options to revive the Alere subsidiary’s chances of getting its Medicare payment privileges restored before Alere faces off next month with Abbott Labs over the two companies’ disputed merger.featured

Judge Orders Abbott and Alere to Cooperate

A Delaware judge directed Abbott Laboratories and Alere to settle their differences over exchanging information on Abbott’s attempts to break its $5.8 billion acquisition of Alere, the Massachusetts maker of medical diagnostic kits.featured

St. Jude/Abbott Deal Highlights Boston Scientific’s Acquisition Appeal

Abbott Labs’ $30 billion cash-and-stock merger with St. Jude Medical is likely to make rival Boston Scientific more vulnerable and turn it into the next acquisition target, Cliff Murphy, a UK-based partner at healthcare-focused M&A advisory ConAlliance Group and a former executive at Abbott Vascular, told CTFN. According to Murphy, the combination, which is not expected to … Read Morefeatured

State Regulators Eye Too Big To Fail for Anthem/Cigna

As the Department of Justice commences its review of the huge mergers in the healthcare insurance arena, state insurance regulators are also expected to focus on the risk profile and liabilities of the combined entities at a time when too big to fail has become a warning signal. “Remember, these healthcare providers are insurers too,” … Read Morefeatured

CVS-Omnicare Deal to Get Close Scrutiny, Long Review

CVS Health Corp.’s acquisition of pharmacy benefits services provider Omnicare Inc. is expected to attract a close regulatory review from the Federal Trade Commission, the same people who blocked Omnicare’s 2012 merger with PharMerica on antitrust grounds, possibly extending completion of the deal beyond its year-end target. “This is going to be a tough one … Read Morefeatured

UnitedHealth-Catamaran Unlikely to Lose Cigna Contract

April 9, 2015 – by Diane Alter – UnitedHealth Group’s $12.8 billion all cash deal for Catamaran Corp. is the largest acquisition in its history. When completed, the March 30 announced merger will solidify UNH’s position as the nation’s third biggest pharmacy benefits manager. Worries have been raised about Catamaran’s contract with Cigna. But Brain … Read Morepublic

UnitedHealth-Catamaran Deal Pressures Pharma Companies

April 6, 2015 – by Ed Roberts – The proposed acquisition of Catamaran Corp. and its pharmacy benefits management business by UnitedHealth Group’s OptumRx is expected to garner close regulatory scrutiny but eventually clear antitrust regulators, in light of recent combinations in the PBM arena cleared by the Federal Trade Commission. “I don’t see competition … Read Morepublic


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.